—Study Strengthens Alzheimer's Link To Cholesterol “Findings on the mechanism of a cholesterol metabolism pathway could aid development of new therapeutics” Findings on the molecular mechanism of a cholesterol metabolism pathway could aid development of a new class of Alzheimer’s disease therapeutics, according to a research report.
by Stuart A. Borman | February 08, 2010
—Research teams characterize complete Alzheimer’s fibrils “Studies provide atomic-level view of full dimeric fibrils of key Alzheimer’s-related peptide” Two research teams have independently obtained atomic-resolution structures of fully formed amyloid-β peptide fibrils that may be involved in Alzheimer’s disease.
by Stu Borman | July 27, 2016
—Lilly Halts Tests On Alzheimer’s Candidate “” Eli Lilly & Co. announced it is halting development of one of its experimental late-stage Alzheimer’s disease treatments because two preliminary Phase III clinical trials indicate that the drug may worsen cognition and the ability to perform daily tasks. The developmental drug, semagacestat, is a γ-secretase inhibitor of amyloid-β, a peptide responsible for plaques that form on the brains of Alzheimer’s patients (C&EN, April 5, page 12). The company says its decision does not affect the Phase III clinical trials of its other Alzheimer’s candidate, solanezumab. /articles/88/i34/Lilly-Halts-Tests-Alzheimers-Candidate.html 20100823 Concentrates 88 34 /magazine/88/8834.html Lilly Halts Tests On Alzheimer’s Candidate Alzheimer�s disease, Eli Lilly & Co., clinical trials con Business Rick Mullin pharmaceuticals Lilly Halts Tests On Alzheimer’s Candidate Chemical & Engineering News Lilly Halts Tests On Alzheimer’s Candidate Lilly Halts Tests On Alzheimer’s Candidate
by Rick Mullin | August 23, 2010
—Alzheimer’s drug candidate trial data disclosed “BACE1 inhibitor verubecestat shows favorable side effect profile” In an early Phase I study, an Alzheimer’s drug candidate showed reduced side effects compared with similar drugs that have failed clinical trials. The agents inhibit BACE1, an enzyme whose activity leads to β-amyloid peptide (Aβ) production. The idea is that inhibiting Aβ formation to reduce growth of Aβ-based plaques in the brains of Alzheimer’s patients may be therapeutic, although it isn’t yet clear how early in the disease process such an intervention would need to be employed to be effective. Several BACE1 inhibitors were withdrawn from trials because of off-target side effects such as liver toxicity.
by Stu Borman | November 07, 2016
—Amyloid Fibril Has Unusual Structure “Structural Biology: Researchers generate Alzheimer’s-related fibril, find it has S-shaped configuration” Many scientists believe that plaques made of amyloid peptide contribute to brain degeneration in people with Alzheimer’s disease. Moreover, fibrils of a 42-amino-acid fragment of this peptide are increasingly thought to be the main culprits in triggering plaque formation.
by Celia Henry Arnaud | May 14, 2015
—Nanotherapy For Alzheimer’s “” Michael Torrice’s news report that transcranial ultrasound, coupled with intravenous injection of lipid-encased microbubbles, clears brain plaques and restores memory in mice is certainly intriguing (C&EN, March 16, page 5). As he notes in his report, this 2015 research study extends and verifies similar effects of ultrasound on another type of Alzheimer’s mouse model reported by a different team of researchers in 2014, all of which indicates noninvasive ultrasound could offer a nonpharmaceutical method to treat Alzheimer’s disease. However, Torrice cites another investigator in this field of research who points out that Alzheimer’s patients already have disrupted blood-brain barriers. Hence any interaction of microbubbles (acoustically activated by ultrasound) with the blood-brain barrier needs to be done very carefully so as not to make matters worse for the Alzheimer’s patient.
October 19, 2015
—'Prochelator' Corrals Copper On Cue “ACS Meeting News: Protease found in brains of those with Alzheimer's triggers release of potentially therapeutic copper chelator” A protease found in the brains of those with Alzheimer's disease can be used to trigger the release of a chelating compound designed to mop up rogue copper, Duke University chemist Katherine J.
by Amanda Yarnell | March 29, 2010